Genetics of multiple myeloma: another heterogeneity level?

被引:114
作者
Corre, Jill [1 ,2 ]
Munshi, Nikhil [3 ,4 ]
Avet-Loiseau, Herve [1 ,2 ]
机构
[1] CHU, IUCT Oncopole, Unit Genom Myeloma, F-31059 Toulouse, France
[2] Inst Natl Sante & Rech Med, Ctr Rech Cancerol Toulouse, U1037, Toulouse, France
[3] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[4] Boston Vet Adm Healthcare Syst, West Roxbury, MA USA
基金
美国国家卫生研究院;
关键词
PLASMA-CELL LEUKEMIA; ADVERSE PROGNOSTIC-FACTOR; IN-SITU HYBRIDIZATION; MONOCLONAL GAMMOPATHY; UNDETERMINED SIGNIFICANCE; MOLECULAR CLASSIFICATION; INTERGROUPE FRANCOPHONE; C-MAF; EXPRESSION; TRANSLOCATIONS;
D O I
10.1182/blood-2014-10-567370
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Our knowledge of myeloma genetics remained limited and lagged behind many other hematologic malignancies because of the inherent difficulties in generating metaphases within the malignant plasma cell clone. With the development of molecular techniques (microarrays and next-generation sequencing), our understanding has been highly improved in the past 5 years. These studies have not only confirmed the prevalence of wide heterogeneity in myeloma at the molecular level, but has also provided a much clearer picture of the disease pathogenesis and progression. Whether these data will enable improvements in the therapeutic approach is still a matter of debate. The next improvement will come from detailed analyses of these molecular features to try to move from a treatment fitted to every patient to individualized therapies, taking into account the complexity of the chromosomal changes, the mutation spectrum, and subclonality evolution.
引用
收藏
页码:1870 / 1876
页数:7
相关论文
共 64 条
[1]
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach [J].
Abramson, JS ;
Shipp, MA .
BLOOD, 2005, 106 (04) :1164-1174
[2]
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma [J].
Affer, M. ;
Chesi, M. ;
Chen, W. D. ;
Keats, J. J. ;
Demchenko, Y. N. ;
Tamizhmani, K. ;
Garbitt, V. M. ;
Riggs, D. L. ;
Brents, L. A. ;
Roschke, A. V. ;
Van Wier, S. ;
Fonseca, R. ;
Bergsagel, P. L. ;
Kuehl, W. M. .
LEUKEMIA, 2014, 28 (08) :1725-1735
[3]
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[4]
Gene expression profile alone is inadequate in predicting complete response in multiple myeloma [J].
Amin, S. B. ;
Yip, W-K ;
Minvielle, S. ;
Broyl, A. ;
Li, Y. ;
Hanlon, B. ;
Swanson, D. ;
Shah, P. K. ;
Moreau, P. ;
van der Holt, B. ;
van Duin, M. ;
Magrangeas, F. ;
Sonneveld, P. Pieter ;
Anderson, K. C. ;
Li, C. ;
Avet-Loiseau, H. ;
Munshi, N. C. .
LEUKEMIA, 2014, 28 (11) :2229-2234
[5]
Targeting the BRAF V600E Mutation in Multiple Myeloma [J].
Andrulis, Mindaugas ;
Lehners, Nicola ;
Capper, David ;
Penzel, Roland ;
Heining, Christoph ;
Huellein, Jennifer ;
Zenz, Thorsten ;
von Deimling, Andreas ;
Schirmacher, Peter ;
Ho, Anthony D. ;
Goldschmidt, Hartmut ;
Neben, Kai ;
Raab, Marc S. .
CANCER DISCOVERY, 2013, 3 (08) :862-869
[6]
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma [J].
Annunziata, Christina M. ;
Davis, R. Eric ;
Demchenko, Yulia ;
Bellamy, William ;
Gabrea, Ana ;
Zhan, Fenghuang ;
Lenz, Georg ;
Hanamura, Ichiro ;
Wright, George ;
Xiao, Wenming ;
Dave, Sandeep ;
Hurt, Elaine M. ;
Tan, Bruce ;
Zhao, Hong ;
Stephens, Owen ;
Santra, Madhumita ;
Williams, David R. ;
Dang, Lenny ;
Barlogie, Bart ;
Shaughnessy, John D., Jr. ;
Kuehl, W. Michael ;
Staudt, Louis M. .
CANCER CELL, 2007, 12 (02) :115-130
[7]
Avet-Loiseau H, 1998, CANCER RES, V58, P5640
[8]
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].
Avet-Loiseau, Herve ;
Attal, Michel ;
Moreau, Philippe ;
Charbonnel, Catherine ;
Garban, Frederic ;
Hulin, Cyrille ;
Leyvraz, Serge ;
Michallet, Mauricette ;
Yakoub-Agha, Ibrahim ;
Garderet, Laurent ;
Marit, Gerald ;
Michaux, Lucienne ;
Voillat, Laurent ;
Renaud, Marc ;
Grosbois, Bernard ;
Guillerm, Gaelle ;
Benboubker, Lotfi ;
Monconduit, Mathieu ;
Thieblemont, Catherine ;
Casassus, Philippe ;
Caillot, Denis ;
Stoppa, Anne-Marie ;
Sotto, Jean-Jacques ;
Wetterwald, Marc ;
Dumontet, Charles ;
Fuzibet, Jean-Gabriel ;
Azais, Isabelle ;
Dorvaux, Veronique ;
Zandecki, Marc ;
Bataille, Regis ;
Minvielle, Stephane ;
Harousseau, Jean-Luc ;
Facon, Thierry ;
Mathiot, Claire .
BLOOD, 2007, 109 (08) :3489-3495
[9]
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival [J].
Avet-Loiseau, Herve ;
Attal, Michel ;
Campion, Loic ;
Caillot, Denis ;
Hulin, Cyrille ;
Marit, Gerald ;
Stoppa, Anne-Marie ;
Voillat, Laurent ;
Wetterwald, Marc ;
Pegourie, Brigitte ;
Voog, Eric ;
Tiab, Mourad ;
Banos, Anne ;
Jaubert, Jerome ;
Bouscary, Didier ;
Macro, Margaret ;
Kolb, Brigitte ;
Traulle, Catherine ;
Mathiot, Claire ;
Magrangeas, Florence ;
Minvielle, Stephane ;
Facon, Thierry ;
Moreau, Philippe .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1949-1952
[10]
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma [J].
Avet-Loiseau, Herve ;
Li, Cheng ;
Magrangeas, Florence ;
Gouraud, Wilfried ;
Charbonnel, Catherine ;
Harousseau, Jean-Luc ;
Attal, Michel ;
Marit, Gerald ;
Mathiot, Claire ;
Facon, Thierry ;
Moreau, Philippe ;
Anderson, Kenneth C. ;
Campion, Loic ;
Munshi, Nikhil C. ;
Minvielle, Stephane .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4585-4590